These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Effect of treatment with botulinum toxin on neurogenic blepharospasm. Elston JS; Russell RW Br Med J (Clin Res Ed); 1985 Jun; 290(6485):1857-9. PubMed ID: 3924284 [TBL] [Abstract][Full Text] [Related]
45. Efficacy and safety of a new bulk toxin of botulinum toxin in cervical dystonia: a blinded evaluation. Racette BA; McGee-Minnich L; Perlmutter JS Clin Neuropharmacol; 1999; 22(6):337-9. PubMed ID: 10626093 [TBL] [Abstract][Full Text] [Related]
47. A preliminary report of the use of botulinum toxin type A in infants with clubfoot: four case studies. Delgado MR; Wilson H; Johnston C; Richards S; Karol L J Pediatr Orthop; 2000; 20(4):533-8. PubMed ID: 10912614 [TBL] [Abstract][Full Text] [Related]
48. Botulinum toxin treatment of lateral axial dystonia in Parkinsonism. Bonanni L; Thomas A; Varanese S; Scorrano V; Onofrj M Mov Disord; 2007 Oct; 22(14):2097-103. PubMed ID: 17685467 [TBL] [Abstract][Full Text] [Related]
49. Long-term results and prognostic factors in the treatment of achalasia with botulinum toxin. Neubrand M; Scheurlen C; Schepke M; Sauerbruch T Endoscopy; 2002 Jul; 34(7):519-23. PubMed ID: 12170400 [TBL] [Abstract][Full Text] [Related]
50. Safety of simultaneous bilateral botulinum toxin injections for abductor spasmodic dysphonia. Stong BC; DelGaudio JM; Hapner ER; Johns MM Arch Otolaryngol Head Neck Surg; 2005 Sep; 131(9):793-5. PubMed ID: 16172357 [TBL] [Abstract][Full Text] [Related]
51. The broadening application of chemodenervation in X-linked dystonia-parkinsonism (Part II): an open-label experience with botulinum toxin-A (Dysport®) injections for oromandibular, lingual, and truncal-axial dystonias. Rosales RL; Ng AR; Santos MM; Fernandez HH Int J Neurosci; 2011; 121 Suppl 1():44-56. PubMed ID: 21348790 [TBL] [Abstract][Full Text] [Related]
52. [Dystonia as the cause of pharyngolaryngeal motility disorders]. Zwirner P; Dressler D HNO; 1995 Aug; 43(8):498-501. PubMed ID: 7558908 [TBL] [Abstract][Full Text] [Related]
53. Meige's syndrome and hemichorea associated with hyperthyroidism. Miao J; Liu R; Li J; Du Y; Zhang W; Li Z J Neurol Sci; 2010 Jan; 288(1-2):175-7. PubMed ID: 19883923 [TBL] [Abstract][Full Text] [Related]
54. [Blepharospasm: treatment with botulinum toxin]. Barbosa ER; Silva HC; Haddad MS; Bittar MS Rev Hosp Clin Fac Med Sao Paulo; 1996; 51(6):220-3. PubMed ID: 9239894 [TBL] [Abstract][Full Text] [Related]
55. [Posterior laryngeal stenosis in patient with Meige's Syndrome]. Pino Rivero V; Marcos García M; Trinidad Ruíz G; Pardo Romero G; González Palomino A; Blasco Huelva A An Otorrinolaringol Ibero Am; 2004; 31(4):349-54. PubMed ID: 15382486 [TBL] [Abstract][Full Text] [Related]
56. Injection of botulinum toxin type B for the treatment of otolaryngology patients with secondary treatment failure of botulinum toxin type A. Guntinas-Lichius O Laryngoscope; 2003 Apr; 113(4):743-5. PubMed ID: 12671439 [No Abstract] [Full Text] [Related]
58. Cranial dystonia, blepharospasm and hemifacial spasm: clinical features and treatment, including the use of botulinum toxin. Kraft SP; Lang AE CMAJ; 1988 Nov; 139(9):837-44. PubMed ID: 3052771 [TBL] [Abstract][Full Text] [Related]
59. Botulinum toxin for people with dystonia treated by an outreach nurse practitioner: a comparative study between a home and a clinic treatment service. Whitaker J; Butler A; Semlyen JK; Barnes MP Arch Phys Med Rehabil; 2001 Apr; 82(4):480-4. PubMed ID: 11295008 [TBL] [Abstract][Full Text] [Related]